{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:22:46Z","timestamp":1781299366801,"version":"3.54.1"},"reference-count":195,"publisher":"Tech Science Press","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.065319","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T02:57:15Z","timestamp":1751338635000},"page":"2279-2307","source":"Crossref","is-referenced-by-count":4,"title":["Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma"],"prefix":"10.32604","volume":"33","author":[{"given":"Prin","family":"Sungwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutatip","family":"Panaampon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratchaneewan","family":"Sumankan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genki","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4251\/wjgo.v5.i7.171","article-title":"Chemotherapy for cholangiocarcinoma: an update","volume":"5","author":"Ram\u00edrez-Merino","year":"2013","journal-title":"World J Gastrointest Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref5","first-page":"351","article-title":"Factors contributing to the high malignancy level of cholangiocarcinoma and its epidemiology","volume":"14","author":"Li","year":"2025","journal-title":"Literat Rev Data Biol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e19386","DOI":"10.7717\/peerj.19386","article-title":"Comparative efficacy of targeted therapy, chemotherapy and their combination for advanced cholangiocarcinoma: a systematic review and network meta-analysis","volume":"13","author":"Liao","year":"2025","journal-title":"PeerJ"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"ii93","DOI":"10.1093\/annonc\/mdi712","article-title":"The role of chemotherapy in cholangiocarcinoma","volume":"16","author":"Thongprasert","year":"2005","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"107064","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2310196","DOI":"10.1080\/07853890.2024.2310196","article-title":"Advances in targeted therapy of cholangiocarcinoma","volume":"56","author":"Li","year":"2024","journal-title":"Ann Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.7314\/APJCP.2016.17.1.401","article-title":"Cholangiocarcinoma patient outcome in northeastern Thailand: single-center prospective study","volume":"17","author":"Luvira","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1002\/cncr.24320","article-title":"A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status","volume":"115","author":"Wittekind","year":"2009","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0344-0338(11)80700-4","article-title":"The pathologist and the residual tumor (R) classification","volume":"190","author":"Hermanek","year":"1994","journal-title":"Pathol-Res Pract"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000511919","article-title":"ERBB2 pathway in biliary tract carcinoma: clinical implications of a targetable pathway","volume":"44","author":"Jacobi","year":"2021","journal-title":"Oncol Res Treat"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2468-1253(21)00171-0","article-title":"Current and emerging therapies for advanced biliary tract cancers","volume":"6","author":"Kam","year":"2021","journal-title":"Lancet Gastroent Hepatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"107457","DOI":"10.1016\/j.actatropica.2024.107457","article-title":"The risk of hepatobiliary complications in Clonorchis and Opisthorchis infection: a systematic review and meta-analysis","volume":"260","author":"Huang","year":"2024","journal-title":"Acta Trop"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.suc.2018.12.004","article-title":"Cholangiocarcinoma","volume":"99","author":"Khan","year":"2019","journal-title":"Surg Clin North Am"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"106133","DOI":"10.1016\/j.actatropica.2021.106133","article-title":"Current status of human liver fluke infections in the Greater Mekong Subregion","volume":"224","author":"Sripa","year":"2021","journal-title":"Acta Trop"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1017\/S0031182022000798","article-title":"Current status of Clonorchis sinensis and clonorchiasis in Korea: epidemiological perspectives integrating the data from human and intermediate hosts","volume":"149","author":"Yoo","year":"2022","journal-title":"Parasitology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"100737","DOI":"10.1016\/j.aohep.2022.100737","article-title":"Clinical treatment of cholangiocarcinoma: an updated comprehensive review","volume":"27","author":"Elvevi","year":"2022","journal-title":"Ann Hepatol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","article-title":"Sorafenib: a review of its use in advanced hepatocellular carcinoma","volume":"69","author":"Keating","year":"2009","journal-title":"Drugs"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/MOG.0000000000000162","article-title":"Genetics of Opisthorchis viverrini-related cholangiocarcinoma","volume":"31","author":"Jusakul","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/liv.14100","article-title":"Medical treatment for cholangiocarcinoma","volume":"39","author":"Adeva","year":"2019","journal-title":"Liver Int"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/cancers16040801","article-title":"Cholangiocarcinoma: recent advances in molecular pathobiology and therapeutic approaches","volume":"16","author":"Khosla","year":"2024","journal-title":"Cancers"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/annonc\/mdv035","article-title":"A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"736049","DOI":"10.1155\/2015\/736049","article-title":"The impact of changed strategies for patients with cholangiocarcinoma in this millenium","volume":"2015","author":"Lindner","year":"2015","journal-title":"HPB Surg"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2188\/jea.JE20180007","article-title":"Cholangiocarcinoma trends, incidence, and relative survival in Khon Kaen, Thailand From 1989 through 2013: a population-based cancer registry study","volume":"29","author":"Kamsa-Ard","year":"2019","journal-title":"J Epidemiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1408852","DOI":"10.3389\/fcell.2024.1408852","article-title":"Overcoming treatment resistance in cholangiocarcinoma: current strategies, challenges, and prospects","volume":"12","author":"Wang","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"114199","DOI":"10.1016\/j.ejca.2024.114199","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: a large real-life worldwide population","volume":"208","author":"Rimini","year":"2024","journal-title":"Eur J Cancer"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/0284186X.2019.1590634","article-title":"Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study","volume":"58","author":"Strijker","year":"2019","journal-title":"Acta Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jamcollsurg.2015.09.005","article-title":"Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection","volume":"221","author":"Groot Koerkamp","year":"2015","journal-title":"J Am Coll Surg"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/SLA.0000000000003801","article-title":"Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma","volume":"273","author":"Cambridge","year":"2021","journal-title":"Ann Surg"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-013-0252-z","article-title":"HER2-positive gastric cancer","volume":"17","author":"Boku","year":"2014","journal-title":"Gast Cancer"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02788354","article-title":"Overexpression of HER2\/neu oncogene in pancreatic cancer correlates with shortened survival","volume":"17","author":"Lei","year":"1995","journal-title":"Int J Pancreatol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","article-title":"HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now","volume":"7","author":"Schlam","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/13543784.2021.1854724","article-title":"Experimental HER2- targeted therapies for biliary tract cancer","volume":"30","author":"Rizzo","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","article-title":"ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling","volume":"16","author":"Graus-Porta","year":"1997","journal-title":"Embo J"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s12282-023-01487-w","article-title":"Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis","volume":"30","author":"Li","year":"2023","journal-title":"Breast Cancer"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S1470-2045(15)00373-3","article-title":"Afatinib alone or afatinib plus vinorelbine versus investigator\u2019s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial","volume":"16","author":"Cortes","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(15)00540-9","article-title":"Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial","volume":"17","author":"Harbeck","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.19.00108","article-title":"Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and\/or trastuzumab: a randomized, phase II study","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2013mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with >\/= 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J Hepatol"},{"key":"ref55","first-page":"6971","article-title":"Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma","volume":"61","author":"Kiguchi","year":"2001","journal-title":"Cancer Res"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.3748\/wjg.v16.i32.4047","article-title":"High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT\/p70S6K","volume":"16","author":"Treekitkarnmongkol","year":"2010","journal-title":"World J Gastroenterol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"120648","DOI":"10.1016\/j.lfs.2022.120648","article-title":"Lactic acidosis promotes aggressive features of cholangiocarcinoma cells via upregulating ALDH1A3 expression through EGFR axis","volume":"302","author":"Thamrongwaranggoon","year":"2022","journal-title":"Life Sci"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"119114","DOI":"10.1016\/j.lfs.2021.119114","article-title":"High glucose upregulates FOXM1 expression via EGFR\/STAT3 dependent activation to promote progression of cholangiocarcinoma","volume":"271","author":"Detarya","year":"2021","journal-title":"Life Sci"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"104655","DOI":"10.1016\/j.critrevonc.2025.104655","article-title":"HER2-targeted therapies: unraveling their role in biliary tract cancers","volume":"208","author":"Theocharopoulos","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ajpath.2024.10.013","article-title":"Genetic, epigenetic, and microenvironmental drivers of cholangiocarcinoma","volume":"195","author":"Putatunda","year":"2025","journal-title":"Am J Pathol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccell.2017.05.009","article-title":"Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma","volume":"32","author":"Chaisaingmongkol","year":"2017","journal-title":"Cancer Cell"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2020.08.006","article-title":"Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer","volume":"105","author":"Hiraoka","year":"2020","journal-title":"Hum Pathol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clini Cancer Res"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cell.2019.08.027","article-title":"Herceptin: a first assault on oncogenes that launched a revolution","volume":"179","author":"Sawyers","year":"2019","journal-title":"Cell"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1038\/onc.2010.151","article-title":"A novel interaction between HER2\/neu and cyclin E in breast cancer","volume":"29","author":"Mittendorf","year":"2010","journal-title":"Oncogene"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-04-0225","article-title":"Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2","volume":"10","author":"Gennari","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"e131882","DOI":"10.1172\/jci.insight.131882","article-title":"CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis","volume":"4","author":"Tsao","year":"2019","journal-title":"JCI Insight"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"112612","DOI":"10.1016\/j.intimp.2024.112612","article-title":"Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms","volume":"138","author":"Panaampon","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/14737140.2019.1596805","article-title":"Pertuzumab for the treatment of breast cancer","volume":"20","author":"Robert","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/cancers10100342","article-title":"Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer","volume":"10","author":"Nami","year":"2018","journal-title":"Cancers"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1158\/1078-0432.CCR-20-3474","article-title":"FDA approval summary: pertuzumab, trastuzumab, and hyaluronidase-zzxf injection for subcutaneous use in patients with HER2-positive breast cancer","volume":"27","author":"Gao","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-981-13-7709-9_12","article-title":"Clinical applications of hyaluronidase","volume":"1148","author":"Weber","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/cncr.34904","article-title":"A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm","volume":"129","author":"Roy","year":"2023","journal-title":"Cancer"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5858\/arpa.2012-0617-OA","volume":"138","author":"Schalper","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"102286","DOI":"10.1016\/j.ctrv.2021.102286","article-title":"Targeting HER2 heterogeneity in breast cancer","volume":"100","author":"Hamilton","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/cancers13051015","article-title":"The exciting new field of HER2-low breast cancer treatment","volume":"13","author":"Eiger","year":"2021","journal-title":"Cancers"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/annonc\/mdl475","article-title":"Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer","volume":"18","author":"Valabrega","year":"2007","journal-title":"Ann Oncol"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"e1362530","DOI":"10.1080\/2162402X.2017.1362530","article-title":"Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles","volume":"6","author":"Martinez","year":"2017","journal-title":"OncoImmunology"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"102113","DOI":"10.1016\/j.tranon.2024.102113","article-title":"Collagen extracellular matrix promotes gastric cancer immune evasion by activating IL4I1-AHR signaling","volume":"49","author":"Zhang","year":"2024","journal-title":"Transl Oncol"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/modpathol.2012.36","article-title":"Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance","volume":"25","author":"Seol","year":"2012","journal-title":"Mod Pathol"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1309\/AJCPIRL4GUVGK3YX","article-title":"HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer","volume":"142","author":"Lee","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1309\/AJCPXTZSKBRIP07W","volume":"136","author":"Allison","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"ref90","first-page":"407","article-title":"Trastuzumab-induced cardiomyopathy","volume":"37","author":"Barish","year":"2019","journal-title":"Cardiol Clin"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11912-021-01114-x","article-title":"Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer","volume":"23","author":"Dent","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"ref93","first-page":"65","article-title":"Discovery research and translation science of trastuzumab deruxtecan, from non-clinical study to clinical trial","volume":"3","author":"Nakada","year":"2021","journal-title":"Translat Regula Sci"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cac2.12577","article-title":"Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","article-title":"Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors","volume":"24","author":"Xu","year":"2021","journal-title":"Gastric Cancer"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3390\/cancers12030670","article-title":"The second generation antibody-drug conjugate SYD985 overcomes resistances to T-DM1","volume":"12","author":"Nadal-Serrano","year":"2020","journal-title":"Cancers"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1016\/j.annonc.2023.09.563","article-title":"386MO Trastuzumab duocarmazine versus physician\u2019s choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial","volume":"34","author":"Aftimos","year":"2023","journal-title":"Ann Oncol"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/cac2.12135","article-title":"Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: an open-label, dose-escalation, phase I study","volume":"41","author":"Hong","year":"2021","journal-title":"Cancer Commun"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"CT053","DOI":"10.1158\/1538-7445.AM2019-CT053","article-title":"Abstract CT053: bAT8001, a potent anti-HER2 antibody drug conjugate with a novel uncleavable linker to reduce toxicity for patients with HER2-positive tumor","volume":"79","author":"Wang","year":"2019","journal-title":"Cancer Res"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"16891","DOI":"10.1038\/s41598-021-96521-2","article-title":"The effects of T-DXd on the expression of HLA class I and chemokines CXCL9\/10\/11 in HER2-overexpressing gastric cancer cells","volume":"11","author":"Nakajima","year":"2021","journal-title":"Sci Rep"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/ph13090245","article-title":"Antibody-drug conjugates: the last decade","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharmaceuticals"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1158\/1078-0432.CCR-23-0103","article-title":"Adavosertib enhances antitumor activity of trastuzumab deruxtecan in HER2-expressing cancers","volume":"29","author":"DiPeri","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1002\/ijc.32408","article-title":"[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification","volume":"145","author":"Takegawa","year":"2019","journal-title":"Int J Cancer"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cortes","year":"2024","journal-title":"Nat Med"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.clbc.2023.09.005","article-title":"Efficacy and safety of trastuzumab deruxtecan in breast cancer: a systematic review and meta-analysis","volume":"23","author":"Dowling","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Ann Oncol"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41467-023-44533-z","article-title":"The HER2-directed antibody-drug conjugate DHES0815A in advanced and\/or metastatic breast cancer: preclinical characterization and phase 1 trial results","volume":"15","author":"Lewis","year":"2024","journal-title":"Nat Commun"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"128876","DOI":"10.1016\/j.bmcl.2022.128876","article-title":"Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates","volume":"72","author":"Thomas","year":"2022","journal-title":"Bioorgan Med Chem Letters"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"P2-13-25","DOI":"10.1158\/1538-7445.SABCS21-P2-13-25","article-title":"Abstract P2-13-25: a phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancer","volume":"82","author":"Krop","year":"2022","journal-title":"Cancer Res"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-19-1004","article-title":"ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers","volume":"19","author":"Skidmore","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"847835","DOI":"10.3389\/fmolb.2022.847835","article-title":"Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers","volume":"9","author":"Yu","year":"2022","journal-title":"Front Mol Biosci"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"PO2-04-03","DOI":"10.1158\/1538-7445.SABCS23-PO2-04-03","article-title":"Abstract PO2-04-03: bL-M07D1, an antibody-drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive\/low-expression and other solid tumors: results from a first-in-human phase 1 study","volume":"84","author":"Song","year":"2024","journal-title":"Cancer Res"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"P6-17-3","DOI":"10.1158\/1538-7445.SABCS18-P6-17-13","article-title":"Abstract P6-17-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers","volume":"79","author":"Hamblett","year":"2019","journal-title":"Cancer Res"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"B130","DOI":"10.1158\/1535-7163.TARG-23-B130","article-title":"Abstract B130: phase 1 study of Zanidatamab Zovodotin (ZW49): safety profile and recommended dose (RD) in patients with human epidermal growth factor 2 (HER2)-positive solid cancers","volume":"22","author":"Oh","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1200\/JCO.2020.38.15_suppl.3551","article-title":"First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer","volume":"38","author":"Park","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/ijms20051115","article-title":"HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer","volume":"20","author":"Rinnerthaler","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/cancers16040800","article-title":"Next-generation HER2-targeted antibody-drug conjugates in breast cancer","volume":"16","author":"Zimmerman","year":"2024","journal-title":"Cancers"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ijc.30500","article-title":"Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients","volume":"140","author":"Bhusari","year":"2017","journal-title":"Int J Cancer"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1515\/nanoph-2021-0119","article-title":"Near infrared photoimmunotherapy of cancer; possible clinical applications","volume":"10","author":"Wakiyama","year":"2021","journal-title":"Nanophotonics"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.3390\/ijms24032655","article-title":"Near infrared photoimmunotherapy: a review of recent progress and their target molecules for cancer therapy","volume":"24","author":"Mohiuddin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"20152","DOI":"10.1038\/s41598-022-24313-3","article-title":"Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in the tumor microenvironment","volume":"12","author":"Sato","year":"2022","journal-title":"Sci Rep"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00259-020-05094-1","article-title":"HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging","volume":"48","author":"Altunay","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/cmdc.201800624","article-title":"Antibody fragment and affibody immunoPET imaging agents: radiolabelling strategies and applications","volume":"13","author":"Fu","year":"2018","journal-title":"ChemMedChem"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/cancers12030651","article-title":"Affibody molecules as targeting vectors for PET imaging","volume":"12","author":"Tolmachev","year":"2020","journal-title":"Cancers"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2967\/jnumed.109.073239","article-title":"Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules","volume":"51","author":"Baum","year":"2010","journal-title":"J Nucl Med"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-1-61779-921-1_7","article-title":"Engineering of affibody molecules for therapy and diagnostics","volume":"899","author":"Feldwisch","year":"2012","journal-title":"Methods Mol Biol"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/374168a0","article-title":"A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks","volume":"374","author":"Greenberg","year":"1995","journal-title":"Nature"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2967\/jnumed.115.162024","article-title":"Phase I study of 68Ga-HER2-nanobody for PET\/CT assessment of HER2 expression in breast carcinoma","volume":"57","author":"Keyaerts","year":"2016","journal-title":"J Nucl Med"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1158\/1078-0432.CCR-17-0310","volume":"23","author":"D\u2019Huyvetter","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3390\/cancers12041017","article-title":"Preclinical targeted \u03b1- and \u03b2-Radionuclide therapy in HER2-positive brain metastasis using camelid single-domain antibodies","volume":"12","author":"Puttemans","year":"2020","journal-title":"Cancers"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2018-05-849802","article-title":"Bifunctional PD-1 \u00d7 \u03b1CD3 \u00d7 \u03b1CD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia","volume":"132","author":"Herrmann","year":"2018","journal-title":"Blood"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41375-018-0014-3","article-title":"Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation","volume":"32","author":"Correnti","year":"2018","journal-title":"Leukemia"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmb.2010.04.001","volume":"399","author":"Johnson","year":"2010","journal-title":"J Mol Biol"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"key":"ref144","unstructured":"GTB-3550 (CD16\/IL-15\/CD33)Tri-Specific Killer Engager (TriKE\u00ae) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory\/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis [Internet]; 2017 [cited 2025 Jun 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03214666."},{"key":"ref145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","article-title":"Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors","volume":"4","author":"Cattaruzza","year":"2023","journal-title":"Nat Cancer"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023","journal-title":"Nat Commun"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ccell.2018.04.003","article-title":"Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade","volume":"33","author":"Geuijen","year":"2018","journal-title":"Cancer Cell"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40262-020-00858-2","article-title":"Population pharmacokinetics of MCLA-128, a HER2\/HER3 bispecific monoclonal antibody, in patients with solid tumors","volume":"59","author":"de Vries Schultink","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"ref152","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2013.07.002","article-title":"Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology","volume":"39","author":"Kalos","year":"2013","journal-title":"Immunity"},{"key":"ref154","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/cancers9090115","article-title":"Chimeric antigen receptor (CAR) T cell therapy for malignant pleural mesothelioma (MPM)","volume":"9","author":"Klampatsa","year":"2017","journal-title":"Cancers"},{"key":"ref157","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nri1248","article-title":"CD28-mediated co-stimulation: a quantitative support for TCR signalling","volume":"3","author":"Acuto","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"ref158","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.4049\/jimmunol.167.11.6123","article-title":"Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28\/CD3 zeta signaling receptor molecule","volume":"167","author":"Hombach","year":"2001","journal-title":"J Immunol"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","article-title":"How do cytotoxic lymphocytes kill cancer cells?","volume":"21","author":"Martinez-Lostao","year":"2015","journal-title":"Clin Cancer Res"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1034707","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells\u2014new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Immunol"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"ref164","first-page":"26","article-title":"Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"ref165","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"ref166","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref167","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"ref168","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"ref169","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"ref170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/PPO.0000000000000032","article-title":"CAR T cells for solid tumors: armed and ready to go?","volume":"20","author":"Kakarla","year":"2014","journal-title":"Cancer J"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"key":"ref172","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol Ther"},{"key":"ref173","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN guidelines(R) insights: biliary tract cancers, version 2.2023","volume":"21","author":"Benson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"273","DOI":"10.18632\/oncotarget.28188","article-title":"Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers","volume":"13","author":"Shah","year":"2022","journal-title":"Oncotarget"},{"key":"ref176","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean cancer study group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref178","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref179","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref180","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","volume":"42","author":"Ohba","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1200\/JCO.24.00868","article-title":"Emerging therapies for the management of human epidermal growth factor receptor 2-\/ERBB2-altered advanced biliary tract cancers","volume":"42","author":"Zeme","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref183","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/ph17081048","article-title":"The pivotal role of preclinical animal models in anti-cancer drug discovery and personalized cancer therapy strategies","volume":"17","author":"Guo","year":"2024","journal-title":"Pharmaceuticals"},{"key":"ref184","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.3390\/ijms21114118","article-title":"Mouse tumor models for advanced cancer immunotherapy","volume":"21","author":"Chulpanova","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref185","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1038\/s41467-019-13471-0","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"ref186","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/2159-8290.CD-18-0044","article-title":"Mouse models for cancer immunotherapy research","volume":"8","author":"Olson","year":"2018","journal-title":"Cancer Discov"},{"key":"ref187","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/hed.27707","volume":"46","author":"Lu","year":"2024","journal-title":"Head Neck"},{"key":"ref188","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.phrs.2017.04.006","article-title":"YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma","volume":"120","author":"Kojima","year":"2017","journal-title":"Pharmacol Res"},{"key":"ref189","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ame2.12349","article-title":"Progress in building clinically relevant patient-derived tumor xenograft models for cancer research","volume":"6","author":"Wang","year":"2023","journal-title":"Animal Model Exp Med"},{"key":"ref190","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4049\/jimmunol.154.1.180","article-title":"Multiple defects in innate and adaptive immunologic function in NOD\/LtSz-scid mice","volume":"154","author":"Shultz","year":"1995","journal-title":"J Immunol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J Immunol"},{"key":"ref192","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/cells8080889","article-title":"Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models","volume":"8","author":"Okada","year":"2019","journal-title":"Cells"},{"key":"ref193","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/cells8050496","article-title":"Establishment of highly transplantable cholangiocarcinoma cell lines from a patient-derived xenograft mouse model","volume":"8","author":"Vaeteewoottacharn","year":"2019","journal-title":"Cells"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.21873\/invivo.13693","volume":"38","author":"Sungwan","year":"2024","journal-title":"In Vivo"},{"key":"ref195","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1038\/s41598-019-42680-2","article-title":"Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts","volume":"9","author":"Liu","year":"2019","journal-title":"Sci Rep"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-9\/OncolRes-33-09-65319\/OncolRes-33-65319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:13:23Z","timestamp":1763345603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n9\/63636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":195,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.065319","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}